|
|
| Line 1: |
Line 1: |
| {{DevelopmentPhase}} | | {{DevelopmentPhase}} |
| | | [[Myocardial Disease]] |
| ==Myocardial Disease==
| | [[Pericardial Disease]] |
| Overall, myocardial diseases can be subdivided into two types: primary and secondary myocardial diseases. Whereas the primary type most commonly has a genetic cause, secondary myocardial diseases are mostly acquired but may be precipitated by a genetic background. Overall, the dilated type is the most prevalent manifestation of cardiomyopathy, and may be induced by a multitude of precipitating factors, such as chronic ischemia or alcohol abuse. The most common primary myocardial disease is hypertrophic cardiomyopathy, which is associated with a wide variety of genetic abnormalities. In the light of their substantially larger prevalence, we will first describe the secondary myocardial diseases, after which the less frequently occurring primary myocardial diseases will be discussed.
| |
| | |
| ===Secondary myocardial disease===
| |
| Myocardial disease subsequent to a known origin is termed secondary myocardial disease. Timely correction of the originating disease may result in reversal of the cardiomyopathy.
| |
| Nine different etiologies can be distinguished:
| |
| *Hypertension
| |
| *Ischaemia
| |
| *Valvular disease
| |
| *Alcohol
| |
| *Metabolic cardiomyopathy
| |
| *Takotsubo cardiomyopathy
| |
| *Peripartum cardiomyopathy
| |
| *Tachycardia
| |
| | |
| ====Hypertension or valvular disease====
| |
| Inadequately treated hypertension or aortic stenosis results in adaptation of the left ventricle by means of hypertrophy. Although primarily considered an adaptive process to systolic overload, hypertrophy of the left ventricle is associated with ventricular dysfunction, arrhythmias, and sudden cardiac death. The process of hypertrophy involves enlargement and proliferation of myocytes, and interstitial fibrosis characterized by deposition of collagen type I and III. With increasing fibrosis, the compliance of the ventricle decreases resulting in loss of diastolic function before systolic function becomes impaired. Within this process of increasing myocardial mass, the coronary vasculature fails to adapt accordingly. In an attempt to accommodate to the increase in myocardial oxygen demand, coronary autoregulatory vasodilation results in an increase in coronary flow by during resting conditions. This partial exhaustion the coronary vasodilator reserve renders the myocardium at relative high risk for ischemia, and hence, patients may suffer from anginal complaints even in the absence of significant coronary artery disease. In patients with LVH, atrial fibrillation and ventricular arrhythmias, including multifocal ventricular extrasystoles, and short runs of ventricular tachycardia, are frequently found. The combination of myocardial fybrosis, maladaptation of the vasculature causing ischemia, autonomic imbalance and a prolongation of the action potential may serve as arrhythmogenic substrate in patients with LVH, resulting in an increased risk of sudden cardiac death.
| |
| | |
| Adequate antihypertensive treatment can regress left ventricular mass. In patients with aortic stenosis, ultimate treatment is valvular replacement to relief the systolic overload of the ventricle. With regression of the ventricle, improved diastolic, and preserved systolic function result, as well as a relief of vascular maladaptation-induced ischemia; the combination of which results in a decrease in cardiovascular events.
| |
| | |
| ====Ischemic cardiomyopathy====
| |
| Chronic myocardial ischemia due to diffuse coronary atherosclerosis can cause cardiomyopathy of the dilated type (DCM). This ischemic cardiomyopathy may occur following one or multiple (silent) myocardial infarction(s), but may also occur from chronic (silent) ischemic myocardial damage. As such, it may be a progressive course of ventricular dilatation and ventricular dysfunction, but may also be the first manifestation of ischemic heart disease.
| |
| | |
| The extent of viable, or hibernating, myocardium determines the clinical relevance of revascularization of the ischemic myocardium. In patients with viable myocardial tissue, reperfusion improves symptoms, and supposedly prognosis. Several non-invasive tests may be used for this purpose, such as nuclear techniques, dobutamine echocardiography or contrast-enhanced cardiac MRI. However, the prognosis of ischemic cardiomyopathy is worse than non-ischemic forms of DCM, mainly due to a high risk of major ventricular arrhythmias. Moreover, subsequent ischemic episodes have a high impact on ventricular function in ischemia-related DCM.
| |
| | |
| As stated previously, revascularization may improve long-term prognosis in patients with objectively viable myocardium. In the absence of viability, routine heart failure therapy is the cornerstone of treatment including beta-blockade and ACE-inhibition (or angiotensine antagonists), and ICD implantation in a selection of patients.
| |
| | |
| =====Alcohol=====
| |
| Long-term alcohol abuse, >80g of alcohol per day (equivalent to 1 liter of wine) for more than 5 years, may lead to a dilated form of cardiomyopathy. Alcohol-induced dilated cardiomyopathy is the leading cause of non-ischemic dilated cardiomyopathy, some claim that it accounts for even up to 50% of cases. Most probably a genetic predisposition for DCM also plays an important role, as excess alcohol consumption itself prevails far more often than alcoholic cardiomyopathy (ACM). Both direct toxic effects of ethanol and its metabolites, as well as frequently occurring concomitant deficiencies of vitamins, minerals or electrolytes may adversely affect myocardial function.
| |
| | |
| Two stages of ACM are recognized when the disease is left untreated. The first stage comprises asymptomatical ventricular dilatation in which diastolic dysfunction may be present, at least partly due to interstitial fibrosis of the myocardium. Fifty percent of asymptomatic patients have echocardiographic signs of LVH with preserved systolic function. The second stage is characterized by impairment of systolic function, and clinically overt heart failure. The prognosis of untreated ACM is comparable to DCM, but is far more favourable in patients that abstain from alcohol use, or dramatically reduce alcohol intake (to less than 60g of ethanol per day). Most of the improvement follows abstinence within 6 months, but ventricular function may improve for up to 2 years. Heart failure therapy may improve ventricular function, but has only been shown to benefit survival in patients that practise abstinence.
| |
| | |
| ====Metabolic cardiomyopathy====
| |
| The group of metabolic cardiomyopathies comprises a heterogenous group of myocardial disease secondary to a disruption in metabolism. Metabolic cardiomyopathy associated with diabetes mellitus is most common. Independent of its influence on hypertension or coronary artery disease, high levels of plasma glucose are increasingly associated with a direct deteriorative effect on ventricular function. Other examples of metabolic disease able to induce cardiomyopathy are nutritional deficits such as thiamine deficiency, or storage diseases, and mutations in AMP kinase.
| |
| | |
| =====Tako-tsubo cardiomyopathy=====
| |
| The prevalence of tako-tsubo cardiomyopathy is largely unknown, but the syndrome predominantly affects women between 60 and 65 years of age. Patients with Tako-tsubo cardiomyopathy present with electrocardiographic features mimicking an acute coronary syndrome in association with elevated cardiac biomarkers, but in the absence of significant coronary artery disease. The disease has inherited its name from the distinct angiographic feature of apical ballooning, resembling an octopus-pot or ''"Tako-tsubo"''. Left ventricular function is typically impaired in the apical and mid ventricular regions, with preserved basal function, although reverse patterns may be seen. High levels of cathecholamines have been suggested to play an important role in the etiology of the syndrome, which can be associated with emotional or physical stress, or in extremes in case of subarachnoidal hemmorhage. This cathecholamine storm may induce severe peripheral coronary spasm, leading to its clinical presentation. Treatment usually consists of aspirin, ACE-inhibitors or angiotensin receptor antogonists in case of preserved blood pressure, beta-blockers to reduce heart rate, and nitrates to counteract coronary spasms. LV function may restore rapidly within a few hours or days, even when admission ejection fraction was severely impaired, and clinical outcome is good although the disease may recur in approximately 5% of patients.
| |
| | |
| =====Peripartum cardiomyopathy=====
| |
| Left ventricular systolic function impairment within 1 month of delivery, or during the first 5 months post partum, in the absence of pre-existing cardiac disease, and in the absence of another recognized cause for the cardiac dysfunction is termed peripartum cardiomyopathy.
| |
| | |
| Presentation is typically with features of left ventricular failure, although many features are undistinguishable from normal changes in pregnancy, due to which mild forms may not even be recognized. An inflammatory component has been suggested, in addition to malnutrition, viral infection, an abnormal immune response, and familial predisposition. Recurrence of the disease in subsequent pregnancies is noted, and makes the previously mentioned etiologies hard to explain. Most probably, peripartum cardiomyopathy results from predisposition to DCM, triggered to uncover by the high cardiovascular burden of the pregnancy.
| |
| | |
| Standard heart failure therapy can be instituted in peripartum cardiomyopathy, but the use of ACE-inhibitors and angiotensin receptor antagonists is contraindicated during pregnancy after the first trimester due to their possible adverse effects on the fetus. In extreme cases, the potential risks for the fetus should however be balanced against the critical need for preservation of ventricular function in order to provide both the mother and the fetus the best chance for a favourable clinical outcome. Pregnancy is also associated with a high risk of thrombo-embolism, as it is a hypercoagulable state per definition, which is enhanced by the presence of an impaired ventricular function in case of peripartum cardiomyopathy, and prophylaxis is therefore recommended.
| |
| | |
| Despite optimal treatment, LV function may normalize in as less as 50% of patients, and may deteriorate to end-stage heart failure in 15%. Potential recurrence in future pregnancies requires counselling of patients to prevent subsequent episodes of symptomatic heart failure and progression of ventricular dysfunction.
| |
| | |
| =====Tachycardia-induced cardiomyopathy=====
| |
| Persistently high heart rates (above 110 beats per minute), such as in sustained ventricular tachycardia, or associated with atrial fibrillation, results in heart failure when left untreated. Normalization of the heart rate by means of beta-blockade subsequently leads to normalization of ventricular function, and is therefore the cornerstone in treatment of tachycardia-induced cardiomyopathy.
| |
| | |
| ===Primary myocardial disease===
| |
| Five different groups of primary myocardial disease exist; which are defined as diseases of the myocardium with impaired cardiac function, also referred to as cardiomyopathies.
| |
| *Hypertrophic cardiomyopathy (HCM)
| |
| *Dilated cardiomyopathy (DCM)
| |
| *Restrictive cardiomyopathy (RCM)
| |
| *Arrythmic cardiomyopathy (ACM)
| |
| *Unclassified cardiomyopathy (UCM)
| |
| | |
| ====Hypertrophic cardiomyopathy====
| |
| The essential characteristics of hypertrophic cardiomyopathy (HCM) are unexplained hypertrophy of the left ventricle in the absence of causal cardiac or systemic disorders. Distinctive features further comprise myocyte disarray, familial occurrence, and an association with sudden cardiac death (SCD).
| |
| | |
| =====Genetics=====
| |
| The identification of the genetic background of HCM resulted in the hypothesis that HCM is a disease of the sarcomere; the contractile unit of the cell. First, mutations were found in the cardiac B-myosin heavy chain gene, while later on other sarcomeric proteins were found to play a role in HCM (Table 1).
| |
| | |
| {| class="wikitable" border="0" cellpadding="1" cellspacing="1" width="400px"
| |
| |-
| |
| ! Table 1. Sarcomeric genes associated with HCM
| |
| |-
| |
| |
| |
| *α-tropomyosin
| |
| *cardiac troponin T
| |
| *troponin I
| |
| *myosin-binding protein C
| |
| *regulatory myosin light chain
| |
| *essential myosin light chain
| |
| *cardiac actin
| |
| *titin
| |
| *troponin C
| |
| *α-myosin heavy chain
| |
| |}
| |
| | |
| It was shown that macroscopic hypertrophy of the myocardium is not essential for neither diagnosis nor prognosis, as mutations for example in troponin T may lead to only minor or no hypertrophy, whereas it is associated with a high incidence of SCD. Nowadays HCM is considered a genetic disorder, inherited mainly autosomal dominant with an incomplete and age-related penetrance. Pathological findings may include myocardial hypertrophy, small-vessel disease and myocyte disarray with or without fibrosis. The prevalence of HCM in the adult population is approximately 1 in 500. But as in only 60% of HCM patients mutations in the abovementioned known sarcomeric genes are present, non-sarcomeric variants of HCM or mutations in regulatory genes, have gained interest. Left ventricular hypertrophy in young children is known most often not to be caused by sarcomeric HCM, but rather by inherited metabolic disorders and syndromes with extracardiac features. These diseases may cause to non-sarcomeric HCM as they include Fabry disease and Danon disease. Recognition and diagnosis of HCM may involve familial counselling, which also helps to find the presence of extracardiac features, and may influence treatment.
| |
| | |
| =====Epidemiology=====
| |
| The prevalence of the HCM phenotype was found to be approximately 0.2%, or 1 in 500, in several epidemiological studies. This frequency is notably higher than its occurrence in daily clinical practice. Hence, a large amount of patients remains undiagnosed, most probably without symptoms of inferences for their prognosis.
| |
| | |
| ====Pathophysiology====
| |
| ''Left ventricular outflow tract obstruction (LVOTO)''
| |
| | |
| The subdivision of HCM into obstructive and non-obstructive forms is clinically important, and is based on the presence or absence of a LV outflow tract gradient during rest and/or after provocation. The presence of such a gradient typically results in a loud apical systolic ejection murmur. The obstruction leads to an increase in intraventricular pressures, impairing LV function by increasing myocardial wall stress and oxygen demand. The obstruction is located either sub-aortic or mid-cavity, where the sub-aortic location is most common and is caused by systolic anterior motion (SAM) of the mitral valve and mid-systolic contact with the ventricular septum. SAM is thought to be facilitated by either an abnormal valvular apparatus loose enough to allow movement, or a hemodynamic force with an anterior component during systole. A drag-effect probably attributes to SAM, which refers to the force exerted by a fluid in the direction of the flow. Apart from its role in sub-aortic obstruction, SAM also results in concomitant mitral regurgitation. The sub-aortic gradient and associated LV pressure increase are pathophysiologically significant and may worsen outcome. LVOTO is an independent predictor for HCM-related death, progression of the disease in terms of New York Heart Association (NYHA) class III or IV, and death due to heart failure or stroke. A gradient threshold of 30 mmHg is prognostically important, but a further increase is not associated with further increased risk. Chronic outflow tract obstruction results in an increase in LV wall stress, myocardial ischemia and fibrosis, and justifies intervention in severely symptomatic patients when optimal medical management is insufficient.
| |
| | |
| HCM patients can be divided into hemodynamic subgroups based on the representative obstructive gradient:
| |
| #Obstructive - gradient under resting conditions equal to or greater than 30 mm Hg (2.7 m/s by Doppler)
| |
| #Provocable obstructive (latent) - gradient less than 30 mm Hg under resting conditions and equal to or greater than 30 mm Hg with provocation
| |
| #Nonobstructive - less than 30 mm Hg under both resting and provocated conditions.
| |
| | |
| LV outflow gradients are routinely measured noninvasively with continuous wave Doppler echocardiography. To define provocable gradients, treadmill or bicycle exercise testing is the preferred stress test, given that HCM-related symptoms are typically elicited with exertion. Pharmacological induction of stress by intravenous infusion of dobutamine is considered contra-indicated.
| |
| | |
| =====Diastolic dysfunction=====
| |
| HCM is, in contrast to other cardiomyopathies, characterized by early occurrence of diastolic dysfunction (both active and passive phases), while systolic function is typically preserved, even before signs of hypertrophy. The passive relaxation during filling of the ventricle is hampered by increased chamber stiffness, increasing filling pressures and decreasing myocardial blood flow. Isovolumetric relaxation in early diastole is prolonged in HCM. Diastolic dysfunction may well lie at the basis of heart failure in non-obstructive HCM with preserved systolic function.
| |
| | |
| =====Ischemia=====
| |
| Myocardial hypertrophy disrupts the subtle equilibrium of blood flow throughout the myocardial layers. Patients with HCM show an increase in coronary blood flow velocity compared to healthy individuals reflecting an autoregulatory decrease in microvascular resistance to adapt to an increase in oxygen demand during resting conditions. The coronary reserve is therefore partly exhausted. Apart from the changes in the coronary microcirculation, systolic extravascular compression might play a role. Most importantly, HCM results in a progressive mismatch between muscle tissue and vascular growth, resulting in a high risk of myocardial ischemia especially for the subendocardial layers. The presence of myocardial ischemia is an important determinant of progression of the disease as it promotes scarring and remodelling of the ventricle.
| |
| | |
| =====Arrhythmia=====
| |
| Myocardial fibrosis associated with HCM is an important arrhythmogenic substrate. Functional consequences of HCM may therefore provide a trigger for ventricular arrhythmias, i.e. ischemia and LVOTO, resulting in non-sustained ventricular tachycardia in approximately 20% of patients. Other functional consequences as diastolic dysfunction, mitral regurgitation, as well as LVOTO are associated with atrial fibrillation (AF) which is observed in 20-25% of HCM patients.
| |
| | |
| =====Wall thinning and cavity dilation=====
| |
| Over time, thinning of the hypertrophic LV wall may occur in patients with severe LVH which may account for the lack of marked echocardiographic LVH in the elderly. While mechanisms of LV remodelling in HCM are still to be defined, cavity dilation and hampered systolic function occur in less than 5% of patients.
| |
| | |
| ====Clinical diagnosis====
| |
| The cornerstone of HCM diagnosis is represented by echocardiography and electrocardiography. In the overall population, the diagnostic criterion of HCM is a maximal wall thickness greater or equal to 15 mm. However, virtually any wall thickness may be associated with the presence of an HCM mutant gene, including wall thickness well within the normal range. Therefore, for both echocardiography and electrocardiography, criteria have been established for the diagnosis of HCM in patients with high risk for HCM. Specificity of these criteria relies significantly on the a-priori chance of HCM, and is therefore only pertinent in first-degree relatives of index cases with confirmed HCM, whom therefore all have a 50% a-priori chance of carrying an HCM mutation. HCM is confirmed in a first-degree relative when either 1 major or 2 minor echocardiographic criteria (Table 2), or 1 minor echocardiographic and 2 minor electrocardiographic criteria (Table 3) are present.
| |
| | |
| =====Echocardiography=====
| |
| Two-dimensional echocardiography is the easiest diagnostic modality for detection of HCM, (Table 2) but cardiac magnetic resonance imaging (CMR) may be used when echocardiography is inconclusive, acoustic windows are insufficient, or when more detailed anatomic information is needed for clinical decision making. Echocardiographic characteristics include thickening of the left ventricular wall without cavity dilatation, and a normal or hyperdynamic left ventricle. Left ventricular outflow tract obstruction is not mandatory for the diagnosis of HCM. Moreover, as mentioned previously, although the diagnosis of HCM is based on a cut-off value for maximal wall thickness of 15 mm in the overall population, multiple HCM-linked mutations are associated with only minor LVH, but represent a high risk of sudden cardiac death.
| |
| | |
| {| class="wikitable" border="0" cellpadding="1" cellspacing="1" width="400px"
| |
| |-
| |
| !Table 2. Echocardiographic diagnostic criteria for HCM in first-degree relatives of index cases with HCM :
| |
| |-
| |
| |'''Major:'''
| |
| |-
| |
| |
| |
| *LV wall thickness =13 mm in the anterior septum or =15 mm in the posterior septum or free wall
| |
| *Severe SAM (septum–leaflet contact)
| |
| |-
| |
| |'''Minor:'''
| |
| |-
| |
| |
| |
| *LV wall thickness of 12mm in the anterior septum or posterior wall or of 14mm in the posterior septum or free wall
| |
| *Moderate SAM (no septum–leaflet contact)
| |
| *Redundant mitral valve leaflets
| |
| |}
| |
| | |
| =====Electrocardiography=====
| |
| Electrocardiographic signs of HCM are typical as the increase in myocardial tissue increases the size of the QRS complexes. Therefore, a typical ECG characteristic of HCM is that it meets voltage criteria for LVH, and shows changes in repolarization (Table 3).
| |
| | |
| {| class="wikitable" border="0" cellpadding="1" cellspacing="1" width="400px"
| |
| |-
| |
| !Table 3. Electrocardiographic diagnostic criteria for HCM in first-degree relatives of index cases with HCM :
| |
| |-
| |
| |'''Major:'''
| |
| |-
| |
| |
| |
| *Left ventricular hypertrophy and repolarization changes
| |
| *T-wave inversion in leads I and aVL (=3mm) (with QRS–T wave axis difference =30°), V3–V6 (=3mm) or II and III and aVF (=5mm)
| |
| *Abnormal Q (>40 ms or >25% R wave) in at least two leads from II, III, aVF (in absence of left anterior hemiblock), V1–V4; or I, aVL, V5–V6
| |
| |-
| |
| |'''Minor:'''
| |
| |-
| |
| |
| |
| *Complete bundle branch block or (minor) interventricular conduction defect (in LV leads)
| |
| *Minor repolarization changes in LV leads
| |
| *Deep S V2 (>25mm)
| |
| |}
| |
| | |
| ====Medical treatment====
| |
| Asymptomatic HCM patients should only receive drugs when symptoms of diastolic dysfunction are present. Verapamil is the treatment of choice, improving diastolic filling and relaxation of the ventricle, decreasing diastolic filling pressures.
| |
| | |
| In symptomatic patients, first line medical treatment consists of a calcium-channel blocker or a betablocker. Verapamil is the first choice, but diltiazem may be used as an alternative. Second, beta-blockers may be used when symptoms prevail, and can be used solitarily or in combination with a calcium-channel blocker. In severely symptomatic patients, diuretics may be used, but with high caution as a small drop in ventricular filling pressure may reduce stroke volume and cardiac output dramatically in HCM patients. A combination can be made with either calcium-channel blockers or beta-blockers.
| |
| | |
| Patients presenting with ventricular tachyarrhythmia or supraventricular atrial fibrillation, amiodarone may be used, and may even improve symptoms and prognosis. Disopyramide has negative inotropic action and results in peripheral vasoconstriction and may improve symptoms when diastolic dysfunction is most prominent (i.e. with preserved ejection fraction).
| |
| | |
| =====Invasive treatment of obstructive HCM=====
| |
| In patients where maximal medical treatment does not control the symptoms, invasive debulking of the myocardial septum may be considered when a marked outflow gradient is present. Treatment options comprise percutaneous alcohol septal ablation, or surgical septal myectomy.
| |
| | |
| ''Surgical myectomy'' has shown excellent long-term result, but 15-20% of patients may suffer from ventricular remodelling and dilatation of the left ventricle. Since the introduction of alcohol ablation, surgical myectomy is reserved for patients with HCM with concomitant disease that independently warrants surgical correction, such as coronary artery bypass grafting of valve repairs, in whom surgical myectomy can be performed as part of the operation.
| |
| | |
| ''Septal ablation'' may be considered in patients with outflow tract gradients of more than 30 – 50 mmHg at rest or 60-100 mmHg after provocation. By injection of 1-3 mL of pure alcohol over 5 minutes into the first or second septal branch, a small myocardial infarction is created. Furthermore, the alcohol induces septal hypokinesis, adding to a reduction of the outflow tract gradient. The gradient may resolve immediately, but this process may take weeks to months. When the outflow tract obstruction persists, patients can be treated a second time.
| |
| | |
| =====Dual chamber pacing=====
| |
| In patients with medically refractory symptoms, whom are suboptimal candidates for invasive treatment, permanent dual chamber pacing may be considered. Pacing may alleviate symptoms by decreasing the outflow tract pressure gradient. However, maintaining a reduction in gradient requires pre-exitation of the right ventricular apex and distal septum, and complete ventricular caption. For optimal results, this should therefore be performed in highly experienced centers only.
| |
| | |
| [[Image:Myocardi1.jpg|400px|thumb|Treatment strategy in HCM]] | |
| | |
| =====Prognosis and outcome=====
| |
| In general, symptoms of HCM increase with age. Mortality rates have been reported to account between 2 and 3% per year. Most importantly, patients with HCM may be at high risk of sudden cardiac death, which may even be its initial presentation, in particular in asymptomatic or mildly symptomatic young patients. HCM is the most common cause of SCD in young people, including athletes. The pathophysiological basis for this predilection is unclarified, and although SCD is most frequent in young people less than 30 to 35 years old, an increased risk for SCD extends thereafter. Although HCM presentation and clinical manifestation is heterogeneous, and it has a relatively low prevalence, clinical markers as shown in Table 4 may identify patients at high risk for SCD. Patients at high risk of SCD are eligible candidates for ICD implantation.
| |
| | |
| {| class="wikitable" border="0" cellpadding="1" cellspacing="1" width="400px"
| |
| |-
| |
| !Table 4. Risk factors for SCD
| |
| |-
| |
| |'''Major'''
| |
| |-
| |
| |
| |
| *Cardiac arrest (ventricular fibrillation)
| |
| *Spontaneous sustained ventricular *tachycardia
| |
| *Family history of premature sudden cardiac death
| |
| *Unexplained syncope
| |
| *LV thickness = 30mm
| |
| *Abnormal exercise blood pressure (increase in systolic blood pressure =20 mmHg)
| |
| *Nonsustained ventricular tachycardia (Holter)
| |
| |-
| |
| |'''Minor'''
| |
| |-
| |
| |
| |
| *Atrial fibrillation
| |
| *Myocardial ischemia
| |
| *LV outflow tract obstruction
| |
| *High-risk mutation
| |
| *Intense (competitive) physical exertion
| |
| *Fibrosis on CMR
| |
| |}
| |
| | |
| ====Dilated cardiomyopathy====
| |
| Dilated cardiomyopathy (DCM) is a primary myocardial disease characterized by ventricular dilatation (one or both ventricles) and impaired myocardial contractility. The impairment of myocardial function cannot be explained by abnormal loading conditions alone, such as valve disease or systemic hypertension. The prevalence of DCM is approximately 36 per 100 000; in at least 50% of patients with DCM, its cause cannot be determined which is referred to as idiopathic DCM. DCM is a condition of which causes and presentations are highly heterogeneous. The diagnosis of idiopathic DCM should only be made after exclusion of the specific cardiomyopathies with a dilated phenotype.
| |
| | |
| =====Genetics=====
| |
| The genetic background of DCM is not as clear as in HCM. Although previously thought to be sporadic, genetic transmission is now thought to account for 30-40% of cases. Multiple genes have been identified that are linked with the occurrence of DCM. Genetic disease may account in part for the primary forms of DCM, but importantly, genetic predisposure may well lead to DCM in case of exposure to precipitating factors such as (emotional) stress, excessive alcohol use or stress upon the cardiovascular system; secondary DCM.
| |
| | |
| The expression of DCM in the familial form is frequently incomplete, and hence its prevalence is supposedly underestimated to a large extent. Even minor abnormalities may progress into overt DCM, and accurate clinical screening of (asymptomatic) relatives is therefore mandatory for early identification of familial DCM cases.
| |
| | |
| =====Pathophysiology=====
| |
| In general, a wide variety of factors can induce or contribute to the development of DCM including arterial hypertension, myocarditis, alcohol abuse or tachyarrhythmias. A subsequent increase in wall stress combined with activation of neurohumoral pathways induces complex cellular and molecular maladaptation, and programmed cell death finally leads to a decrease in the number of functioning cardiomyocytes. This process of cardiac remodelling itself results in systolic and/or diastolic dysfunction, leading to increased wall stress, and thereby creating a vicious circle of progressive systolic dysfunction (Figure 1).
| |
| | |
| [[Image:Process of cardiac remodelling.svg|thumb|400px|Figure 1. Process of cardiac remodelling]]
| |
| | |
| The failing myocardium has several distinct factors promoting apoptosis of cardiomyocytes in vitro; cathecholamines, wall stress, angiotensin II, nitric oxide and inflammatory cytokines. Hence, medical management of DCM aims at antagonizing these pathways, reducing stress signalling in, and remodelling of the failing heart.
| |
| | |
| =====Clinical diagnosis=====
| |
| The most common initial manifestation of DCM is heart failure, in which clinical symptoms do not differ from heart failure of other causes. An important feature of the physical examination is a gallop rhythm of S3 and S4. S3 and S4 may fuse in tachycardic patients with new onset of heart failure. Special attention should focus upon excluding valvular heart disease as a cause, and excluding right-sided involvement.
| |
| | |
| Diagnostic testing in DCM focuses on identification of reversible causes, which focuses on the history (alcohol use) but also includes plasma biomarker evaluation, non-invasive imaging, electrocardiography, and exercise testing.
| |
| | |
| ''Echocardiography'' is an important diagnostic modality in DCM, as it can be used to assess both the size and shape of the LV, but also to determine LV function by assessing the LV ejection fraction (LVEF). Furthermore, valvular heart disease or pericardial abnormalities can be excluded. CMR evaluation may contribute to identification of specific cardiomyopathic conditions, especially when acoustic windows are suboptimal. The cardiac response to exertion is an established risk factor in DCM patients, which may be evaluated by cardiopulmonary exercise testing. Dilatation of the ventricular cavity results in myocyte stretch. In response, B-type natriuretic peptide is released, which is a well-known neurohormone that can be used to evaluate progression of DCM and to guide medical treatment. High plasma concentrations (twice the ULN) are strongly associated with increased long-term mortality.
| |
| | |
| ''Electrocardiography'' does not provide an accurate diagnostic mean in DCM, but can identify several characteristics associated with unfavourable prognosis, or identify factors contributing to DCM, and therefore is an important modality in the evaluation of DCM patients. Sinus tachycardia is frequently present, and non-specific ST-segment or T-wave changes as well as changes in P-wave morphology may well be present. AF is an important feature associated with high mortality; its control may contribute to improve cardiac performance. Furthermore, the presence of AF may indicate tachycardia-induced DCM. 24-hour Holter monitoring can reveal decreased heart rate variability or complex ventricular arrhythmias which are associated with a high risk for mortality. Finally, prolonged QTc intervals are associated with high mortality.
| |
| | |
| =====Management of DCM=====
| |
| Management of symptoms and progression of DCM accord to those described in the management of heart failure. Hence, also in DCM, diuretics and neurohumoral antagonists provide the basis for management of symptoms, and preventive ICD or pacemaker implantation is indicated in selected patients. Most importantly, surgical or percutaneous correction of underlying conditions facilitating progression of DCM, such as coronary artery disease, valvular heart disease or congenital abnormalities is warranted.
| |
| | |
| =====Specific dilated cardiomyopathies=====
| |
| It is important to note that there are several causes of secondary DCM. A foursome of these is of utmost importance to recognize early on, as accurate diagnosis influences the patients treatment strategy and chance for complete recovery.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Tako-tsubo'''''
| |
| |}
| |
| Is described under ‘Secondary Myocardial Disease’
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Peripartum cardiomyopathy'''''
| |
| |}
| |
| Is described under ‘Secondary Myocardial Disease’
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Tachycardia-induced cardiomyopathy'''''
| |
| |}
| |
| Is described under ‘Secondary Myocardial Disease’
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Alcoholic cardiomyopathy'''''
| |
| |}
| |
| Is described under ‘Secondary Myocardial Disease’
| |
| | |
| =====Cardiomyopathy in muscular dystrophy=====
| |
| Defined as primary disorders of skeletal and/or cardiac muscles of genetic etiology, muscular dystrophies were primarily described based upon the distribution and extent of skeletal muscle involvement. The involvement of the heart was commonly attributed to processes extrinsic to the heart, resulting in restrictive lung disease, subsequent pulmonary hypertension, and secondary myocardial dysfunction. Intrinsic dysfunction is increasingly recognized as an important etiology for myocardial function impairment in the presence of muscular dystrophy. Typical forms of dystrophy are based on deficiency of dystrophin, of which mutations have been described in X-linked DCM. Furthermore, histological changes were found in the myocardium similar to those in skeletal muscles, which suggest a common etiology, and moreover cardiac manifestations may be present even in the absence of myopathic symptoms.
| |
| | |
| Treatment of cardiac dysfunction is treated according to the nature of cardiac involvement. Conduction disorders may present which require pacing, and standard heart failure therapy may be instituted in case of ventricular dilatation and functional impairment. Ventricular tachyarrhythmias may be found in particular in myotonic dystrophia, and require the implantation of an internal cardiac defibrillator to prevent its associated sudden cardiac death.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Prognosis and outcome'''''
| |
| |}
| |
| DCM has a highly variable clinical course. Approximately half of DCM patients respond well to routine heart failure medication, and a minority of patients even shows an improving clinical course. Conversely, a subgroup can be identified with a highly unfavourable clinical course, not responsive to heart failure medication and rapidly progressing to inotropy- or LVAD-dependency. Overall, 5-year survival rates approximate 30%.
| |
|
| |
| =====Restrictive cardiomyopathy=====
| |
| Restrictive cardiomyopathy is characterized by an increase in ventricular wall stiffness, impairing its diastolic function. Systolic function is usually preserved in early stages of the disease, but may deteriorate with progression of the disease. RCM is less frequent in the developed world than the previously described HCM and DCM, but is an important cause of death in Africa, India, South and Central America, and Asia due to the high endemic incidence of ''endomyocardial fibrosis''. The spectrum of restrictive cardiomyopathies can be classified as shown in Table 5, according to its cause.
| |
| | |
| The most important specific causes of RCM will be discussed in detail below.
| |
| | |
| An important differentiation is that between RCM and constrictive pericarditis. Constrictive pericarditis is similarly characterized by impaired ventricular filling with preserved systolic function, but may be adequately treated by pericardiectomy, which makes this distinction of major clinical importance.
| |
| | |
| {| class="wikitable" border="0" cellpadding="1" cellspacing="1" width="400px"
| |
| |-
| |
| !Table 5. -- Classification of Restrictive Cardiomyopathy
| |
| |-
| |
| |'''Myocardial'''
| |
| |-
| |
| |'''''Noninfiltrative'''''
| |
| *Idiopathic cardiomyopathy
| |
| *Familial cardiomyopathy
| |
| *Hypertrophic cardiomyopathy
| |
| *Scleroderma
| |
| *Pseudoxanthoma elasticum
| |
| *Diabetic cardiomyopathy
| |
| |-
| |
| |'''''Infiltrative'''''
| |
| *Amyloidosis
| |
| *Sarcoidosis
| |
| *Hurler disease
| |
| *Fatty infiltration
| |
| |-
| |
| |'''''Storage Disease'''''
| |
| *Hemochromatosis
| |
| *Fabry disease
| |
| *Gaucher disease
| |
| *Glycogen storage disease
| |
| |-
| |
| |'''''Endomyocardial'''''
| |
| *Endomyocardial fibrosis
| |
| *Hypereosinophilic syndrome
| |
| *Carcinoid heart disease
| |
| *Metastatic cancers
| |
| *Radiation ∗
| |
| *Toxic effects of anthracycline ∗
| |
| *Drugs causing fibrous endocarditis(serotonin, methysergide, ergotamine, mercurial agents, busulfan)
| |
| |-
| |
| |bgcolor="#FFFFCC"|''∗ Adapted from Kushwaha S, Fallon JT, Fuster V: Restrictive cardiomyopathy. N Engl J Med 336:267, 1997. Copyright 1997, Massachusetts Medical Society.''
| |
| |}
| |
| | |
| =====Infiltrative=====
| |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Amyloidosis'''''
| |
| |}
| |
| Amyloidosis is a disease that results from tissue deposition of fibrils that have a distinct secondary structure of a beta-pleated sheet configuration, leading to characteristic histological changes. Amyloid depositions can occur in almost any organ, but usually remains clinically undetected unless extensive depositions are present.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Types of amyloidosis'''''
| |
| |}
| |
| The most frequent types of amyloidosis are the AL (primary) and AA (secondary) types. AL amyloidosis is a plasma cell dyscrasia, which can occur solitarily or in association with multiple myeloma. AA amyloidosis can be considered a complication of chronic inflammatory disease states such as rheumatoid arthritis, in which the depositions consist of fragments of serum amyloid A, which is an acute phase reactant.
| |
| | |
| Hereditary amyloidosis has been increasingly recognized in the last decade, and results from mutations in the gene for thransthyretin. Some mutations are clinically limited to the myocardium. Its incidence increases with increasing age, with a predilection for men, but its prognosis is better than that of the AL type. Senile systemic amyloidosis results from deposition of normal wild-type transthyretin. This form of amyloidosis is clinically predominated by an infiltrative cardiomyopathy, but progression is slow and prognosis is better than of other acquired forms.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Cardiac amyloidosis'''''
| |
| |}
| |
| Cardiac amyloidosis is a progressive infiltrative cardiomyopathy. The primary form carries the highest cardiac involvement of approximately one third to half of patients, where deposits may be present even in the absence of clinical symptoms. Secondary amyloidosis is less frequently accompanied by cardiac infiltration, approximately 5% of cases, and is less likely associated with ventricular dysfunction due to a smaller size and more favourable location of the depositions. Familial amyloidosis is associated with clinical signs of cardiac involvement in a quarter of patients, typically presenting after the age of 35 with a distinct involvement of the cardiac conduction system. In senile amyloidosis, the extent of deposits may vary widely from solitarily atrial involvement up to extensive ventricular infiltration.
| |
| | |
| =====Clinical manifestations=====
| |
| Apart from the occurrence of cardiac disease in the presence of known AL amyloidosis or connective tissue disease or other chronic inflammatory disorders, cardiac amyloidosis should be considered in case of:
| |
| *Restrictive cardiomyopathy of unknown origin
| |
| *Left ventricular hypertrophy with a converse low-voltage ECG
| |
| *Congestive heart failure of unknown origin, not responding to contemporary medical management.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Clinical diagnosis'''''
| |
| |}
| |
| Diagnostic testing should include a 12-lead ECG, possibly with Holter monitoring, and routine echocardiography. Specific characteristics are a low-voltage 12-lead ECG with increase septal and posterior wall ventricular thickness.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Physical examination'''''
| |
| |}
| |
| A physical examination may reveal an elevated jugular venous pressure, and signs of systemic edema. Auscultation frequently reveals an apical murmur due to mitral regurgitation, and a third heart sound, but the presence of a fourth heart sound may exclude amyloidosis, as atrial infiltration causes impaired atrial contraction.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Electrocardiography'''''
| |
| |}
| |
| Routine 12-lead ECG shows low voltage in the limb leads, and a pseudoinfarct pattern in approximately 50% of patients. Furthermore, conduction abnormalities occur frequently, as does atrial fibrillation.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Echocardiography'''''
| |
| |}
| |
| Thickening of the left ventricular wall with diastolic dysfunction are early echocardiografic features of the disease. In advancing disease, wall thickening increases, resulting in a restrictive cardiomyopathy. “Sparkling” myocardium is a distinct characteristic of cardiac amyloidosis, referring to an increased echogenicity of the myocardium. However, only a minority of patients has this pattern. Doppler evaluation shows a restrictive pattern with E dominance and a short deceleration time.
| |
| Furthermore, intracardiac thrombus is common, which is associated with atrial fibrillation and left ventricular diastolic dysfunction.
| |
| | |
| The thickening of the ventricular wall caused by amyloidosis may be misinterpreted as hypertrophy on echocardiography. An important distinctive characteristic of amyloidosis is the voltage-to-mass ratio. Unlike normal hypertrophic myocardium, the increased ventricular mass in amyloidosis is associated with a decrease in electrocardiographic voltage.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Management'''''
| |
| |}
| |
| Few treatments for cardiac amyloidosis exist, and those available are dependent on the type of amyloidosis present. Hence, typing of the disease is pertinent. AL amyloidosis may be treated with chemotherapy using alkylating agents alone or in combination with bone marrow transplantation. Heart transplantation in combination with bone marrow transplantation after high-dose chemotherapy was shown to be result in approximately a third of treated patients surviving over 5 years, but as the great majority of patients with AL amyloidosis has severe non-cardiac amyloidosis, most patients are not suitable transplant candidates. Patients with other types of amyloidosis frequently have less affected hearts, and progression of the disease is slow. AA amyloidosis may respond to anti-inflammatory and immunosupressive drugs that reduce production of the acute-phase reactant protein. If heart failure is present, it is usually more prone to routine medical treatment to reduce symptoms. If needed, heart transplantation can be performed successfully. In patients where transthyretine is the amyloidogenic protein, liver transplantation may be curative as tranthyretine is produced in the liver, but the cardiac disease may progress regardless in some patients.
| |
| | |
| Overall, caution should be taken in prescribing digitalis, nifedipine, verapamil and ACE-inhibitors to cardiac amyloidosis patients. There is a high susceptibility to digitalis intoxication, nifedipine-induced hemodynamic deterioration, verapamil-induced left ventricular dysfunction, and ACE-inhibitor induced profound hypotension. If atrial fibrillation is present, or systolic ventricular function is severely impaired anticoagulation is indicated to prevent intracardiac thrombi. In selected patients with conduction disorders, pacemaker implantation may be considered. If ventricular function is severely impaired, ICD implantation may be considered. Nonetheless, prognosis of especially AL amyloidosis is poor.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Sarcoidosis'''''
| |
| |}
| |
| Sarcoidosis is a multisystem inflammatory condition characterized by the formation of non-caseating granulomas, most frequently affecting the lungs and lymphatic system. Myocardial involvement is seen in one quarter of cases only. Genetic factors are suggested as there was found to be an aggregation of cases within families.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Pathophysiology'''''
| |
| |}
| |
| Non-caseating granulomas may infiltrate the myocardium, leading to fibrotic scarring of the myocardium. Involvement of the myocardium is usually patchy, resulting in a relatively high likelihood of false-negative results from biopsy. Cardiac sarcoidosis must be differentiated from chronic active myocarditis and giant cell myocarditis.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Clinical diagnosis'''''
| |
| |}
| |
| Patients may present with syncope, heart block or congestive heart failure. Sudden cardiac death may well be the initial manifestation of the disease due to malignant ventricular arrhythmias, but both atrial and ventricular arrhythmia is common at initial presentation. Symptoms of heart failure may result from direct myocardial involvement, but can also be due to extensive pulmonary fibrosis; cor pulmonale.
| |
| | |
| Physical examination may include signs of extracardiac sarcoidosis, a right sided third heart sound, and both S3 and S4, as well as murmurs of tricuspid regurgitation or mitral regurgitation.
| |
| | |
| Initial consideration of the diagnosis is often based on chest radiographs showing bilateral hilar lymfadenopathy. CMR is emerging as a highly sensitive and specific test for sarcoidosis, and nuclear imaging techniques may show regional perfusion defect due to the granulomatous inflammation on SPECT, or focal uptake on PET CT. electrocardiography is useful to assess the extent of conduction system involvement. Echocardiography shows left ventricular dilatation with hypokinesis, right ventricular enlargement and hypertrophy and possibly left ventricular aneurysm formation.
| |
| | |
| Minimal evaluation of a patient suspected of cardiac sarcoidosis consists of a 12-lead ECG, Holter monitoring and echocardiography.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Management'''''
| |
| |}
| |
| Early detection of the disease is critical for its clinical course. Immunosuppression using corticosteroids to halt the progression of inflammation is the treatment of choice in sarcoidosis, to which myocardial dysfunction, conduction disturbances, and arrhythmias may all respond. Most important is the differentiation of sarcoidosis from giant cell myocarditis, which is a more aggressive disorder requiring intensive medical and mechanical support and frequently necessitating heart transplantation. Pacemaker or ICD implantation is indicated in patients with conduction disorders or malignant arrhythmias, as medical treatment is usually ineffective in these cases.
| |
| | |
| =====Storage diseases=====
| |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Hemochromatosis'''''
| |
| |}
| |
| Hemochromatosis is defined as a disorder of the iron metabolism, resulting in accumulation of iron in parenchymal tissues. In particular cardiac, liver, gonadal and pancreatic involvements are typical for hemochromatosis, in which the toxicity of redox-active iron results in organ dysfunction. Typically, hemochromatosis leads to a combination of heart failure, cirrhosis, impotence, diabetes and arthritis. Although several organ systems are usually involved, cardiac complications predominate the initial presentation, which are dependent on the site and amount of cardiac depositions. DCM is the typical phenotype of cardiac involvement, but a restrictive pattern may be present.
| |
| | |
| The most frequent, adult-onset, form of hemochromatosis was found arise from mutations in the HFE-gene, coding for a transmembrane protein involved in iron uptake in the liver and the intestine. Less frequently, mutations in the transferrine 2-encoding gene may result in hemochromatosis. The juvenile form of hemochromatosis results from mutations in the genes encoding hepcidin and hemojuvelin. The disease may also be acquired and result from ineffective erythropoiesis secondary to a defect in haemoglobin synthesis, chronic liver disease, chronic excessive oral or parenteral intake of iron, or from multiple blood transfusions.
| |
| | |
| Three stages of the natural history of adult-onset hemochromatosis can be differentiated. The first stage, the biochemical stage, is characterized by an iron overload which remains confined to the plasma compartment. Transferrin saturation is increased. The second phase, the deposition phase, is characterized by iron accumulation in parenchymal tissues, accommodated by an increase in serum ferritine levels. The third and final stage is that of organ dysfunction.
| |
| Juvenile hemochromatosis is a more rapidly progressing disease, which leads to early organ dysfunction, around the age of 30, and is frequently characterized by premature death due to severe cardiac complications.
| |
| | |
| The invariably present symptoms of heart failure may frequently be accompanied by arrhythmias, especially ventricular extrasystoles, supraventricular tachycardia, and atrial fibrillation or flutter; either due to atrial iron depositions, or ventricular dysfunction resulting in increased ventricular pressure. Furthermore, conduction system involvement may lead to AV block or sick sinus syndrome.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Diagnostic features'''''
| |
| |}
| |
| Symptoms at initial presentation may vary. Echocardiography may show increased left ventricular wall thickness, ventricular dilatation, and ventricular dysfunction. CMR imaging represents a sensitive mean and may aid in early detection of the disease. Electrocardiographic characteristics include ST-segment and T-wave abnormalities as well as supraventricular arrhythmias, but occur as the disease advances. Biochemical testing reveals increased elevated transferrine saturation, increase plasma iron levels with low or normal iron binding capacity.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Management'''''
| |
| |}
| |
| Repeated phlebotomy is the cornerstone of hemochromatosis treatment, although chelating agents such as deferoxamine may be considered. Early detection of the disease is critical, as depletion of iron overload may result in complete reversal of symptoms at this stage. Evidence was found that a threshold exists beyond which iron depletion does not result in recovery of function. At end-stage disease, heart transplantation is a viable option with good survival rates. Importantly, screening of first degree relatives is important to ensure early detection of hereditary forms of hemochromatosis.
| |
| | |
| ====Fabry disease (angiokeratoma corporis diffusum universale)====
| |
| Fabry disease is an X-linked inheritable deficiency of the lysosomal alpha-galactosidase A, resulting in an accumulation of glycosphingolipids in the lysosomes. There is a wide variety of know mutations, which all result in a different level of alpha-galactosidase inactivity, and hence, clinical manifestation may range from isolated myocardial disease to systemic involvement.
| |
| | |
| Patients may suffer from angina pectoris and myocardial infarction due to the accumulation of the aforementioned lipids in the endothelium of the coronary arteries, but the epicardial vessels show no abnormalities on angiography. Ventricular function is hampered due to thickening of the ventricular walls, which results in impaired diastolic compliance with a preserved systolic function, and may even precede myocardial hypertrophy. Other common features of the disorder include systemic hypertension, congestive heart failure, and mitral valve prolapse. The surface electrocardiogram may reveal a short P-R interval, atrioventricular block, and ST-segment and T wave abnormalities. Echocardiography may be inconclusive, but CMR imaging may differentiate Fabry disease from other infiltrative processes. Definite diagnosis is made on endomyocardial biopsy. Treatment of Fabry is safe and effective, and consists of enzyme-replacement therapy.
| |
| | |
| ====Gaucher Disease====
| |
| Gaucher disease is an inheritable deficiency of beta-glucosidase, resulting in accumulation of cerebrosides. Cardiac involvement results in impaired cardiac function due to reduced ventricular compliance. Treatment of Gaucher disease consists of enzyme replacement therapy, or liver transplantation as a last resort. Response to treatment with respect to recovery of symptoms is heterogeneous.
| |
| | |
| ====Glycogen storage disease====
| |
| Glycogen storage disease may result in cardiac involvement in case of type II, III, IV and V, but survival until adulthood is rare except for type III disease. Cardiac involvement is characterized by left ventricular hypertrophy, electrographically and echocardiographically, but cardiac symptoms are frequently absent.
| |
| | |
| ====Endomyocardial====
| |
| =====Endomyocardial fibrosis=====
| |
| Endomyocardial fibrosis is an important cause of congestive heart failure in equatorial Africa. Prevalence up to 20% has been reported, mostly familial in children or young adults, although symptoms occurred only in a minority of detected cases. The disease predominantly occurs in black individuals, but may rarely present in white subjects.
| |
| | |
| The fibrous lesions hamper cardiac function by impairing the inflow of the ventricles, affecting the left or both ventricles most commonly. Solitaire right-sided involvement is less frequent, occurring in approximately 10% of cases. Symptoms are concordant with the ventricles involved, an atrial fibrillation and ascites are known factors associated with a poor prognosis. Clinical diagnosis is based upon clinical presentation, lab testing, and angiography. Left-sided myocardial biopsy is relatively contraindicated, as it may result in systemic emboli.
| |
| | |
| Endomyocardial fibrosis is a relentless disease, half of patients not making it beyond 2 years after detection, depending on the extent of symptoms at presentation. Medical management is only effective in the early stages of the disease, and is aimed at relief of symptoms. Surgical correction of the clinical consequences of the disease, i.e. valve replacement, improves hemodynamic characteristics, but mortality is high, and fibrosis may reoccur.
| |
| | |
| =====Hypereosinophilic syndrome: Löffler Endocarditis=====
| |
| The hypereosinophilic syndrome is a systemic disease, involving several organ systems. Cardiac involvement, Löffler endocarditis, is usually present when eosinophil counts are high for a longer period of time. The eosinophilia itself may occur from several different causes.
| |
| | |
| Histopathology shows eosinophilic myocarditis extending into the subendocardium, endocardial thickening, and inflammation of the small intramural coronary vessels.
| |
| | |
| Clinical features of the disease are weight loss, cough, fever, and a rash. Cardiac involvement may not induce clinical symptoms in the early stages of the disease, but as the disease progresses as much as 50% of patients develop cardiomegaly or congestive heart failure.
| |
| | |
| Cardiomegaly may be suspected on chest radiography, and the electrocardiogram shows non-specific abnormalities of the ST-segment and T-waves. Conduction defects may also occur. Echocardiography often shows a normal systolic function, and may show apical obliteration by thrombus. Obliteration of the apex with a preserved systolic function is a key characteristic of the disease on angiography. Endomyocardial biopsy can provide the diagnosis, but may be false-negative.
| |
| | |
| Routine care applies to these patients. Diuretics and neurohumoral blockade are appropriate, as is anticoagulation. Corticosteroids and cytotoxic drugs increase survival in patients with Löffler endocarditis, and interferon may be used as a last option in refractory patients. Surgical therapy may be considered as palliative treatment in the fibrotic fase of the disease.
| |
| | |
| ====Arrythmic cardiomyopathy: Arrhythmogenic Right Ventricular Cardiomyopathy====
| |
| Arrhythmogenic Right Ventricular Cardiomyopathy, (ARVC, or ARVD: Arrhythmogenic Right Ventricular Disease) is characterized by fatty replacement and fibrosis of the heart. Most commonly, the right ventricle apex and outflow tract are involved. However, the left ventricle can be affected too. As a result of the fatty replacement and fibrosis, ventricular arrhythmias are common in this disease and can lead to palpitations, syncope and sudden death. At more advanced ages, right ventricular failure can occur.
| |
| | |
| ARVC is a progressive disease, and its incidence is estimated to be 1:3.000-1:10.000. The disease usually manifests at adolescence. Although the diagnosis is more often confirmed in athletes, physical activity is not thought to have a causal relationship with the disease. ARVC can occur in families; more than 9 different chromosomal defects have been described, most often with autosomal dominant inheritance. One unique form of ARVC, called Naxos disease (after the Greek island where it was first diagnosed), has an autosomal recessive pattern of inheritance.
| |
| | |
| =====Diagnosis=====
| |
| ARVC is a difficult diagnosis to make. Therefore, the European Society of Cardiology has created a list of diagnostic criteria for the diagnosis of ARVC, which were updated in 2009 (Table 6). An [http://www.arvc.ca/pdg/public.php?rep=arvc_cri online calculator] can help in assessing the risk in an individual patient.
| |
| | |
| {| class="wikitable" border="0" cellpadding="1" cellspacing="1" width="600px"
| |
| |-
| |
| |-
| |
| ! Table 6. The Revised Task Force Criteria for ARVD / ARVC Revised Task Force Criteria
| |
| |-
| |
| !'''I. Global or regional dysfunction and structural alterations ∗'''
| |
| |-
| |
| |'''Major'''
| |
| |-
| |
| |'''By 2D echo:'''
| |
| *Regional RV akinesia, dyskinesia, or aneurysm
| |
| *and 1 of the following (end diastole):
| |
| **PLAX RVOT =32 mm (corrected for body size [PLAX/BSA] =19 mm/m<sup>2</sup>)
| |
| **PSAX RVOT =36 mm (corrected for body **[PSAX/BSA] =21 mm/m<sup>2</sup>)
| |
| **or fractional area change =33%
| |
| |-
| |
| |'''By MRI:'''
| |
| *Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
| |
| *and 1 of the following:
| |
| **Ratio of RV end-diastolic volume to BSA =110 mL/m<sup>2</sup> (male) or =100 mL/m<sup>2</sup> (female)
| |
| **or RV ejection fraction =40%
| |
| |-
| |
| |'''By RV angiography:'''
| |
| *Regional RV akinesia, dyskinesia, or aneurysm
| |
| |-
| |
| |'''Minor'''
| |
| |-
| |
| |'''By 2D echo:'''
| |
| *Regional RV akinesia or dyskinesia
| |
| *and 1 of the following (end diastole):
| |
| **PLAX RVOT =29 to <32 mm (corrected for body size [PLAX/BSA] =16 to <19 mm/m<sup>2</sup>)
| |
| **PSAX RVOT =32 to <36 mm (corrected for body size [PSAX/BSA] =18 to <21 mm/m<sup>2</sup>)
| |
| **or fractional area change >33% to =40%
| |
| |-
| |
| |'''By MRI:'''
| |
| *Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
| |
| *and 1 of the following:
| |
| **Ratio of RV end-diastolic volume to BSA =100 to <110 mL/m<sup>2</sup> (male) or =90 to <100 mL/m<sup>2</sup> (female)
| |
| **or RV ejection fraction >40% to =45%
| |
| |-
| |
| !II. Tissue characterization of wall
| |
| |-
| |
| |'''Major'''
| |
| |-
| |
| |Residual myocytes <60% by morphometric analysis (or <50% if estimated), with fibrous replacement of the RV free wall myocardium in =1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
| |
| |-
| |
| |'''Minor'''
| |
| |-
| |
| |Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in =1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
| |
| |-
| |
| !III. Repolarization abnormalities
| |
| |-
| |
| |'''Major'''
| |
| |-
| |
| |Inverted T waves in right precordial leads (V<sub>1</sub>, V<sub>2</sub>, and V<sub>3</sub>) or beyond in individuals >14 years of age (in the absence of complete right bundle-branch block QRS =120 ms)
| |
| |-
| |
| |'''Minor'''
| |
| |-
| |
| |Inverted T waves in leads V<sub>1</sub> and V<sub>2</sub> in individuals >14 years of age (in the absence of complete right bundle-branch block) or in V<sub>4</sup>, V<sub>5</sub>, or V<sub>6</sub>
| |
| |-
| |
| |Inverted T waves in leads V1, V<sub>2</sub>, V<sub>3</sub>, and V<sub>4</sub> in individuals >14 years of age in the presence of complete right bundle-branch block
| |
| |-
| |
| !IV. Depolarization/conduction abnormalities
| |
| |-
| |
| |'''Major'''
| |
| |-
| |
| |
| |
| *Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V<sub>1</sub> to V<sub>3</sub>)
| |
| | |
| |-
| |
| |'''Minor'''
| |
| |-
| |
| |
| |
| *Late potentials by SAECG in =1 of 3 parameters in the absence of a QRS duration of =110 ms on the standard ECG
| |
| *Filtered QRS duration (fQRS) =114 ms
| |
| *Duration of terminal QRS <40 µV (low-amplitude signal duration) =38 ms
| |
| *Root-mean-square voltage of terminal 40 ms =20 µV
| |
| *Terminal activation duration of QRS =55 ms measured from the nadir of the S wave to the end of the QRS, including R´, in V<sub>1</sub>, V<sub>2</sub>, or V<sub>3</sub>, in the absence of complete right bundle-branch block
| |
| |-
| |
| !V. Arrhythmias
| |
| |-
| |
| |'''Major'''
| |
| |-
| |
| |
| |
| *Nonsustained or sustained ventricular tachycardia of left bundle-branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)
| |
| |-
| |
| |'''Minor'''
| |
| |-
| |
| |
| |
| *Nonsustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis
| |
| *>500 ventricular extrasystoles per 24 hours (Holter)
| |
| |-
| |
| !VI. Family history
| |
| |-
| |
| |'''Major'''
| |
| |-
| |
| |
| |
| *ARVC/D confirmed in a first-degree relative who meets current Task Force criteria
| |
| *ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative
| |
| *Identification of a pathogenic mutation† categorized as associated or probably associated with ARVC/D in the patient under evaluation
| |
| |-
| |
| |'''Minor'''
| |
| |-
| |
| |
| |
| *History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force criteria
| |
| *Premature sudden death (<35 years of age) due to suspected ARVC/D in a first-degree relative
| |
| *ARVC/D confirmed pathologically or by current Task Force Criteria in second-degree relative
| |
| |-
| |
| |
| |
| *PLAX indicates parasternal long-axis view; RVOT, RV outflow tract; BSA, body surface area; PSAX, parasternal short-axis view; aVF, augmented voltage unipolar left foot lead; and aVL, augmented voltage unipolar left arm lead.
| |
| *Diagnostic terminology for original criteria: This diagnosis is fulfilled by the presence of 2 major, or 1 major plus 2 minor criteria or 4 minor criteria from different groups. Diagnostic terminology for revised criteria: definite diagnosis: 2 major or 1 major and 2 minor criteria or 4 minor from different categories; borderline: 1 major and 1 minor or 3 minor criteria from different categories; possible: 1 major or 2 minor criteria from different categories.
| |
| |-
| |
| |∗ Hypokinesis is not included in this or subsequent definitions of RV regional wall motion abnormalities for the proposed modified criteria.
| |
| | |
| † A pathogenic mutation is a DNA alteration associated with ARVC/D that alters or is expected to alter the encoded protein, is unobserved or rare in a large non–ARVC/D control population, and either alters or is predicted to alter the structure or function of the protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree. E.g.: in TMEM43, DSP, PKP2, DSG2, DSC2, JUP.
| |
| |}
| |
| | |
| =====Treatment=====
| |
| Treatment focuses on avoiding complications.
| |
| *Medication:
| |
| **Anti-arrhythmics: Sotalol better than Amiodarone.
| |
| **ACE-inhibitors to prevent cardiac remodelling
| |
| *ICD implantation is recommended for the prevention of sudden cardiac death in patients with ARVC with documented sustained VT or VF who are receiving chronic optimal medical therapy.
| |
| *ICD implantation can be considered for the prevention of sudden cardiac death in patients with ARVC with extensive disease, including those with left ventricular involvement, 1 or more affected family member with SCD, or undiagnosed syncope when ventricular tachycardia or ventricular Fibrillation has not been excluded as the cause of syncope, who are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year.
| |
| *Radiofrequency ablation can be useful as adjunctive therapy in management of patients with ARVC with recurrent ventricular tachycardia, despite optimal anti-arrhythmic drug therapy.
| |
| | |
| ====Unclassified Cardiomyopathy: Left ventricular non-compaction====
| |
| Left ventricular non-compaction (LVNC) is characterized by distinct structural abnormalities:
| |
| | |
| A two-layered structure of the myocardium, with a thin compacted epicardial band and a thick non-compacted endomyocardial part, overall resulting in a thickened myocardium. LVNC is diagnosed by the ratio between the maximal non-compacted and compacted myocardial layer thickness measured during end-systole. In adults, a non-compacted/compacted thickness ratio of =2 confirms the diagnosis, whereas a ratio of =1.4 is considered diagnostic in children. The non-compacted layer is further characterized by prominent trabeculations, with intertrabecular spaces in direct connection with the left ventricular cavity. The non-compacted regions are predominantly found in the lateral, apical or inferior wall of the left ventricle. Where normal myocardium, originally consisting of a sponge-like structure of myocardial fibres, shows a pattern of basal to apical, and epicardial to endocardial compaction of the myocardial fibres during the 5th to 8th week of embryonal development, non-compaction supposedly originates from halting of this process due to a genetic defect.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Clinical Presentation and Diagnosis'''''
| |
| |}
| |
| Age of onset may be highly variable, with cyanosis, failure to thrive or dysmorphic features described in the neonatal period, to adult patients presenting with LV failure or ventricular arrhythmia. Possibly, sudden cardiac death entails one of the manifestations of LVNC, although evidence is only limited at this moment. Owing to technical advances in the field of echocardiography, predominantly an increase in image resolution, LVNC has only recently been recognized as an independent entity in the spectrum of cardiomyopathies, which supposedly has frequently been misdiagnosed as HCM in the past.
| |
| | |
| Two-dimensional echocardiography entails the cornerstone of LVNC diagnostics, enhanced by intravenous contrast agents if necessary. Magnetic resonance imaging may pose an option in case acoustic windows are insufficient. ECG abnormalities in patients with LVNC are mostly non-specific.
| |
| | |
| Considering the genetic background of LVNC, inheriting most commonly autosomal dominant, echocardiographic evaluation of family members of LVNC patients is pertinent.
| |
| | |
| {| class="wikitable" cellpadding="0" cellspacing="0" border="0" width="100%"
| |
| |-
| |
| |bgcolor="#F0F8FF"|'''''Treatment and Prognosis'''''
| |
| |}
| |
| | |
| Treatment strategies are mainly extrapolated from other cardiomyopathies: standard heart failure therapy in case of LV dysfunction, beta-blockade and/or amiodarone in non-sustained VT in the absence of LV dysfunction, and ICD placement indicated in patients with LVEF <35%, sustained VT or recurrent unexplained syncope. Routine anticoagulation in not indicated, but anticoagulation may be instituted in case of ventricular dilatation or systolic LV function impairment.
| |
| | |
| The prognosis of LVNC has currently not yet been defined. One small report indicates a high mortality risk, owing to a high prevalence of sudden death, but community-based populations may well show a different prognosis as many patients with LVNC are non-symptomatic at the initial diagnosis.
| |
| | |
| ==Pericardial Disease==
| |
| The pericardium comprises two layers; the visceral layer that adheres to epicardial surface of the heart, and the parietal layer that surrounds most of the heart. Pericardial disease is common, and diagnosis is usually straightforward as the pericardium reacts to disruption by a wide variety of agents and processes in a relatively uniform manner. Typical presentation is with chest pain and fever, production of pericardial fluid with possible cardiac tamponade, or a constrictive pattern by thickening, retraction and calcification.
| |
| | |
| ===Acute pericardial syndromes===
| |
| ====Cardiac Tamponade====
| |
| An increase in intrapericardial pressure, resulting in compression of the heart, and thereby a resitriction of cardiac inflow, is termed cardiac tamponade. Tamponade may result from pericardial effusion of any cause. The intrapericardial pressure importantly determines to what extent cardiac inflow is decreased, but two factors need to be taken into consideration. First, intrapericardial pressure is determined not only on the amount of fluid that accumulates, but also on the rate with which this accumulation proceeds, and the available distensibility of the pericardium. Chronic effusions may therefore lead to small increases in intrapericardial pressures in the presence of large fluid accumulations, and small accumulations may directly lead to severe cardiac tamponade for example after free wall rupture. Second, the intravascular volume and intra-atrial, and -ventricular pressures determine at what pressure inflow becomes impaired. When intrapericardial pressure exceeds right atrial pressure (approximately 8 mmHg), tamponade typically follows. However, in patients in whom intra-atrial pressure is decreased, for example due to volume depletion, tamponade may already occur at lower intrapericardial pressures; low-pressure cardiac tamponade.
| |
| | |
| With increasing intrapericardial pressure, clinical features increase with severe hemodynamic compromise as its end stage. First, small changes in intrapericardial pressure induce subtle changes in arterial pressure, cardiac output, and variations in arterial pressure with inspiration (pulsus paradoxus). When intrapericardial pressure reaches levels similar to right atrial and diastolic right ventricular pressure echocardiographic evidence of tamponade may be found in diastolic collapsing of the right atrium, and increased variations of blood flow velocity over the cardiac valves with respiration. Fulminant clinical tamponade presents with symptoms that depend on its etiology. Acute cardiac tamponade based upon aortic or free wall rupture presents with syncope and sudden collapse, whereas tamponade in the setting of an acute inflammatory pericardits may present with pericardial chest pain, and dyspnoea. Therefore, in patients presenting with chest discomfort, dyspnoea, tachycardia or tachypnoea, cardiac tamponade should be suspected when jugular distension, hypotension or pulsus paradoxus is present. Auscultation may reveal pericardial friction rub, and heart sounds may be faint. Echocardiography shows pericardial effusion, the previously mentioned diastolic collapsing of the cardiac cavities, increased flow velocity over tricuspid and pulmonary valves, and decreased flow velocity over the aortic and mitral valves.
| |
| | |
| When secondary to inflammatory pericarditis, tamponade up to moderate severity may be treated by anti-inflammatory drugs. In severe tamponade, pericardiocentesis should be performed to immediately alleviate intrapericardial pressure. Surgical drainage should be considered when pericardiocentesis is unsuccessful, or when tamponade recurs.
| |
| | |
| ====Acute pericarditis====
| |
| Acute inflammation of the pericardium may result from a wide variety of etiologies (Table 1), and typically presents with chest pain, a pericardial friction rub on auscultation, and repolarization changes on the electrocardiogram.
| |
| | |
| {| class="wikitable" border="0" cellpadding="1" cellspacing="1" width="400px"
| |
| |-
| |
| !Table 1. Causes of acute pericarditis
| |
| |-
| |
| |
| |
| *Acute idiopathic pericarditis
| |
| *Infectious pericarditis:
| |
| **Viral
| |
| **Tuberculosis
| |
| **Bacterial
| |
| **Others
| |
| *Postpericardiotomy syndrome
| |
| *Postmyocardial infarction pericarditis
| |
| *Renal insufficiency
| |
| *Neoplastic disease
| |
| *Chest trauma
| |
| *Irradiation
| |
| *Collagen diseases
| |
| |}
| |
| | |
| Patients present with a rapid-onset chest pain syndrome located precordial and retrosternal, and radiating to the subclavian region, the back and the trapezoid region. Chest pain is of moderate severity, lasting for several days, and increases with inspiration or chest movement. Patients typically alleviate the pain by sitting and leaning forward.
| |
| | |
| A pericardial friction rub is pathognomonic of pericarditis, and ECG changes are frequently present, which comprise diffuse concave ST-segment elevation, with positive T-waves in several leads. Atrial injury is accompanied by PR-segment depression. After several hours to a few days, ST-segments return iso-electric, and negative T-waves may occur subsequently, which may persist for several weeks although they frequently normalize within days. Pericardial effusion may be present, and can be diagnosed by chest X-ray when fluid accumulation exceeds 250mL, or by echocardiography.
| |
| | |
| Although initial presentation may mimic ST-segment elevation myocardial infarction (STEMI). Onset of chest pain is less abrupt in acute pericarditis, and varies with respiration. Furthermore, diffuse ST-segment changes are present in pericarditis, whereas STEMI presents with ST-segment elevation, and reciprocal depression, in leads corresponding to the ischemic myocardium. Biomarkers can be positive in both syndromes.
| |
| | |
| Treatment consists of aspirin while pain and fever are present, which usually adequately alleviates symptoms. Another option is NSAIDs, which are recommended when aspirin in insufficient or contraindicated. Corticosteroids should, however, be avoided as they are associated with relapsing pericarditis. Hospital admission may be necessary in patients with high fever, large effusions or cardiac tamponade.
| |
| | |
| ====Recurrent pericarditis====
| |
| In 8 to 80% of patients, pericarditis recurs after a first episode of acute pericarditis. A continuous type, in which symptoms recur shortly after cessation of anti-inflammatory therapy, and an intermittent type, in which symptom-free periods of more than 6 weeks separate recurrences, can be distinguished. Frequently resulting from inadequate therapy or corticosteroid-use during the initial episode, subsequent recurrences are usually less severe. A recurrence should be treated according to the same procedures as for the first event. Pericardiectomy may be considered the last resort in severely refractory recurrent pericarditis, but its results are unpredictable. Prognosis of the disease is excellent, as severe complications are rare.
| |
| | |
| ===Pericardial effusion===
| |
| Fluid accumulation in the pericardium, pericardial effusion, is a common finding on routine echocardiography, and is asymptomatic in the absence of inflammation or cardiac tamponade. It may result from any disease of the pericardium, or be iatrogenic. Most frequently it results from idiopathic pericarditis, malignancy, or iatrogenic defects (Table 2).
| |
| | |
| {| class="wikitable" border="0" cellpadding="1" cellspacing="1" width="400px"
| |
| |-
| |
| !Table 2. Causes of pericardial effusion
| |
| |-
| |
| |
| |
| *Any type of acute pericarditis
| |
| *Cardiac surgery
| |
| *Acute myocardial infarction
| |
| *Heart failure
| |
| *Chronic renal failure
| |
| *Iatrogenic
| |
| *Metabolic diseases
| |
| *Autoimmune diseases
| |
| *Trauma
| |
| *Chylopericardium
| |
| *Pregnancy
| |
| *Idiopathic
| |
| |}
| |
| | |
| Where the use of electrocardiography and chest radiography is limited in pericardial effusion, echocardiography may reveal an echo-free space in the anterior or posterior sacs, present throughout the cardiac cycle. The absence of cavity collaps indicates the absence of tamponade.
| |
| | |
| Treatment of pericardial effusion depends on the extent of symptoms, and the etiology underlying the effusion. Asymptomatic mild pericardial effusion (<10mm sum of echo-free spaces in anterior and posterior sacs) may be left untreated. Control echocardiography is indicated at 3-6 months. In moderate (10-20mm sum of echo-free space) to large effusions, a complete history, routine physical examination, ECG, chest radiography and routine blood analysis is indicated. Treatment is then based upon its expected etiology, standard treatment with aspirin or NSAIDs to relief pain, with invasive procedures indicated in case of tamponade with hemodynamic compromise or recurrent pericarditis as discussed previously. Specific etiologies of pericardial effusion must be managed accordingly.
| |
| | |
| ====Chronic pericardial effusion====
| |
| Pericardial effusion is considered chronic when moderate to large effusions persist for at least 3 months. Resulting most frequently from idiopathic cause, intrapericardial pressure is frequently elevated in these patients, which may lead to unexpected tamponade in up to 30% of patients. Hence, pericardiocentesis is indicated to alleviate the fluid accumulation, and pericardiectomy should be considered when large effusions recur. Long term outcome is excellent with this approach.
| |
| | |
| ===Constrictive pericarditis===
| |
| The pericardial layers may become rigid, thickened, and may fuse, resulting in restriction of cardiac filling; constrictive pericarditis. In contrast to cardiac tamponade, where cardiac is hampered throughout diastole, cardiac filling is prohibited in the last two-thirds of diastole in constrictive pericarditis, with preserved abrupt filling in early diastole.
| |
| | |
| ====Chronic constrictive pericarditis====
| |
| Any form of pericarditis may end in constrictive pericarditis, presenting with chronic fatigue, dyspnoea, jugular distension, proto-diastolic pericardial knock, hepatomegaly, ascites, peripheral oedema, and pleural effusion. Atrial fibrillation is a common finding, and diffuse flattened or negative T-waves are usually present. These suggestive clinical findings, in addition to a physiology of restriction or constriction on echocardiography, and the presence of a thickened pericardium provide the diagnosis. However, a thickened pericardium may be absent, which does not rule out constrictive pericarditis. Pericardiectomy is the only effective treatment, which should be instituted shortly after diagnosis, as surgical mortality increases with increasing age and functional impairment.
| |
| | |
| {| class="wikitable" border="0" cellpadding="1" cellspacing="1" width="600px"
| |
| |-
| |
| |-
| |
| !colspan="2"|Table 3. Differential diagnosis between chronic constrictive pericarditis and restrictive cardiomyopathy
| |
| |-
| |
| !width="50%"|Constrictive pericarditis
| |
| !Restrictive cardiomyopathy
| |
| |-
| |
| |colspan="2"|'''Physical examination'''
| |
| |-
| |
| |Early diastolic precordial impulse
| |
| |Apical impulse may be prominent
| |
| |-
| |
| |colspan="2"|'''Pericardial knock'''
| |
| |-
| |
| |No murmur
| |
| |Third sound may be present
| |
| | |
| Regurgitant murmur common
| |
| |-
| |
| |colspan="2"|'''Electrocardiography'''
| |
| |-
| |
| |Low voltage
| |
| | |
| Frequent atrial fibrillation
| |
| | |
| Normal QRS complex
| |
| |Low voltage in amiloidosis
| |
| | |
| Frequent atrial fibrillation
| |
| | |
| Bundle branch block
| |
| |-
| |
| |colspan="2"|'''Chest radiogram'''
| |
| |-
| |
| |Pericardial calcification possible
| |
| |Non-specific cardiomegaly
| |
| |-
| |
| |colspan="2"|'''Echocardiography'''
| |
| |-
| |
| |Normal wall thickness
| |
| |Pericardial thickening
| |
| |-
| |
| |colspan="2"|'''Diastolic notch of interventricular septum'''
| |
| |-
| |
| |Increased wall thickness (amyloidosis)
| |
| |Enlarged left and right atria
| |
| |-
| |
| |colspan="2"|'''Doppler studies e' septal =8 cm/sec and normal S' mitral annular velocity'''
| |
| |-
| |
| |Mitral inflow increase during expiration
| |
| | |
| Mitral flow propagation velocity M-mode colour =45cm/s
| |
| | |
| Increased diastolic flow reversal in the hepatic vein with expiration e' septal <8cm/s and decreased mitral annular velocity
| |
| |Mitral inflow velocity without respiratory variation
| |
| | |
| Mitral flow propagation velocity M-mode colour <45cm/s
| |
| | |
| Increased diastolic flow reversal in the hepatic vein with inspiration
| |
| |-
| |
| |colspan="2"|'''Cardiac catheterization'''
| |
| |-
| |
| |RVEDP and LVEDP usually equal
| |
| | |
| RV systolic pressure <50mmHg
| |
| |RVEDP >one-third of RV systolic pressure
| |
| | |
| LVEDP often >5mm greater than RVEDP
| |
| |-
| |
| |colspan="2"|'''Endomyocardial biopsy'''
| |
| |-
| |
| |Normal or non-specific changes
| |
| |May reveal specific causes
| |
| |-
| |
| |colspan="2"|'''CT/MR imaging'''
| |
| |-
| |
| |Pericardium thickened or calcified
| |
| |Normal pericardium
| |
| |-
| |
| |colspan="2"|'''CT, computer tomography; e', e wave velocity by tissue velocity imaging;'''
| |
| |-
| |
| |LVEDP, left ventricular end-diastolic pressure;
| |
| | |
| MR, magnetic resonance;
| |
| | |
| |RV, right ventricular;
| |
| | |
| RVEDP, right ventricular end-diastolic pressure.
| |
| |}
| |
| | |
| ====Subacute elastic constriction====
| |
| Elastic cardiac constriction, in contrast to the rigid chronic constriction, results from an elastic thickened pericardium, which still allows distension during the respiratory cycle. It may be seen in the first period after acute inflammatory or infectious pericarditis, and may progress to chronic pericardial constriction, or prove to be a transient process.
| |
| | |
| ====Effusive-constrictive pericarditis====
| |
| Presenting with cardiac tamponade on admission, effusive-constrictive pericarditis is characterized by a persistent increase in right atrial and end-diastolic ventricular pressures after intrapericardial pressure has been alleviated by pericardiocentesis. Apart from idiopathic cases, it may accompany chest radiation, cardiac surgery, neoplasia, and tuberculosis. Most frequently, the disease will progress to persistent constriction for which epicardiectomy is indicated, but it may rarely be a transient phenomenon.
| |
| | |
| ====Transient cardiac constriction====
| |
| Clinical and hemodynamic features of constrictive pericarditis may dissipate spontaneously, which is seen commonly (20%) in idiopathic acute pericarditis with effusion, but may also be seen in tuberculous and purulent pericarditis. Hence, a primarily conservative approach may alleviate the need for epicardiectomy.
| |
| | |
| ===Specific types of pericardial disease===
| |
| ====Infectious pericarditis====
| |
| =====Idiopathic/Viral pericarditis=====
| |
| This is the most frequent form of pericarditis, accounting for more than 80% of cases, of which most probably are of viral etiology, but virus identification is cumbersome and no treatment consequences exist. The disease is frequently accompanied by pericardial effusion, cardiac tamponade, and left pleural effusion, but prognosis is notably good.
| |
| | |
| =====Tuberculous pericarditis=====
| |
| Predominantly found in developing countries, and in patients with human immunodeficiency virus (HIV) infection, tuberculous pericarditis is rare in the Western world and presents typically with symptoms of acute pericarditis. Identification of Mycobacterium tuberculosis yields the diagnosis, which may be found in pericardial or other bodily fluids, or may be assumed when caseating granulomas are found. Routine tuberculosis treatment, comprising three antituberculous agents, yields a good prognosis although a subacute constrictive pericarditis is common, requiring pericardiectomy but with excellent outcome.
| |
| | |
| =====Purulent pericarditis=====
| |
| Purulent pericarditis has a high mortality, owing to the intangible diagnosis and the related severity of the underlying disease. Cardiac tamponade is frequent, and acute constrictive pericarditis may occur. The disease should be considered in all patients presenting with high fever, dyspnoea, and tachycardia with intrathoracic or subphrenic infections, or sepsis with symptoms that suggest pericardial involvement. Pericardiocentesis is indicated even in the absence of tamponade when the disease is confirmed, and appropriate antibiotic treatment should be instituted. Long-term prognosis is however excellent in patients that survive until discharge.
| |
| | |
| ====Post myocardial infarction pericarditis====
| |
| Pericardial effusion frequently occurs in the early stage after myocardial infarction, which remains asymptomatic and can be left untreated. Within the first week after myocardial infarction, acute pericarditis may occur, which is related to the extent of the infarction. The presence of a pericardial rub may distinguish chest pain and ECG changes resulting from acute pericarditis from recurrent ischemia.
| |
| | |
| Weeks to months after myocardial infarction, pleuropericarditis of autoimmune nature may prevail, termed Dressler’s syndrome. However, this syndrome is rare, and treatment with corticosteroids yields a good prognosis.
| |
| | |
| ====Neoplastic pericarditis====
| |
| Lung cancer is the most frequent cause of neoplastic pericarditis. Cardiac tamponade in patients with a history of malignancy, in the absence of inflammatory signs indicates a possible malignant etiology, as is lack of response to NSAIDs in this patient group. When the effusion is indeed of malignant origin (approximately 40% of cases), treatment aims at alleviation of symptoms and the prevention of recurrences. A balance should be sought between pericardiocentisis in which recurrence is frequent, and pericardiectomy, which may be overly aggressive in this critically ill subset of patients.
| |
| | |
| ====Hypothyroidism====
| |
| With increasing severity of primary hypothyroidism, the prevalence of pericardial effusion increases. Thyroid hormone replacement therapy results in remission of the effusion.
| |
| | |
| ====Post-pericardiotomy pericarditis====
| |
| Pericarditis is common after cardiac surgery (18%), of which the etiology is unclear although an autoimmune origin has been proposed. In contrast to other forms of pericarditis, post-pericardiotomy pericarditis may be effectively treated with corticosteroids and NSAIDs.
| |
This website is currently being developed and in a testing phase.